Mandy A Allison1, Laura P Hurley2, Lauri Markowitz3, Lori A Crane4, Michaela Brtnikova5, Brenda L Beaty6, Megan Snow6, Janine Cory7, Shannon Stokley7, Jill Roark7, Allison Kempe5. 1. Department of Pediatrics, Adult and Child Center for Health Outcomes Research and Delivery Science, and mandy.allison@ucdenver.edu. 2. Adult and Child Center for Health Outcomes Research and Delivery Science, and Division of Internal Medicine, Denver Health, Denver, Colorado; 3. National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention and. 4. Adult and Child Center for Health Outcomes Research and Delivery Science, and Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, and Children's Hospital Colorado, Aurora, Colorado; 5. Department of Pediatrics, Adult and Child Center for Health Outcomes Research and Delivery Science, and. 6. Adult and Child Center for Health Outcomes Research and Delivery Science, and. 7. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND AND OBJECTIVES: Because physicians' practices could be modified to reduce missed opportunities for human papillomavirus (HPV) vaccination, our goal was to: (1) describe self-reported practices regarding recommending the HPV vaccine; (2) estimate the frequency of parental deferral of HPV vaccination; and (3)identify characteristics associated with not discussing it. METHODS: A national survey among pediatricians and family physicians (FP) was conducted between October 2013 and January 2014. Using multivariable analysis, characteristics associated with not discussing HPV vaccination were examined. RESULTS: Response rates were 82% for pediatricians (364 of 442) and 56% for FP (218 of 387). For 11-12 year-old girls, 60% of pediatricians and 59% of FP strongly recommend HPV vaccine; for boys,52% and 41% ostrongly recommen. More than one-half reported ≥25% of parents deferred HPV vaccination. At the 11-12 year well visit, 84% of pediatricians and 75% of FP frequently/always discuss HPV vaccination. Compared with physicians who frequently/always discuss , those who occasionally/rarely discuss(18%) were more likely to be FP (adjusted odds ratio [aOR]: 2.0 [95% confidence interval (CI): 1.1-3.5), be male (aOR: 1.8 [95% CI: 1.1-3.1]), disagree that parents will accept HPV vaccine if discussed with other vaccines (aOR: 2.3 [95% CI: 1.3-4.2]), report that 25% to 49% (aOR: 2.8 [95% CI: 1.1-6.8]) or ≥50% (aOR: 7.8 [95% CI: 3.4-17.6]) of parents defer, and express concern about waning immunity (aOR: 3.4 [95% CI: 1.8-6.4]). CONCLUSIONS: Addressing physicians' perceptions about parental acceptance of HPV vaccine, the possible advantages of discussing HPV vaccination with other recommended vaccines, and concerns about waning immunity could lead to increased vaccination rates.
BACKGROUND AND OBJECTIVES: Because physicians' practices could be modified to reduce missed opportunities for human papillomavirus (HPV) vaccination, our goal was to: (1) describe self-reported practices regarding recommending the HPV vaccine; (2) estimate the frequency of parental deferral of HPV vaccination; and (3)identify characteristics associated with not discussing it. METHODS: A national survey among pediatricians and family physicians (FP) was conducted between October 2013 and January 2014. Using multivariable analysis, characteristics associated with not discussing HPV vaccination were examined. RESULTS: Response rates were 82% for pediatricians (364 of 442) and 56% for FP (218 of 387). For 11-12 year-old girls, 60% of pediatricians and 59% of FP strongly recommend HPV vaccine; for boys,52% and 41% ostrongly recommen. More than one-half reported ≥25% of parents deferred HPV vaccination. At the 11-12 year well visit, 84% of pediatricians and 75% of FP frequently/always discuss HPV vaccination. Compared with physicians who frequently/always discuss , those who occasionally/rarely discuss(18%) were more likely to be FP (adjusted odds ratio [aOR]: 2.0 [95% confidence interval (CI): 1.1-3.5), be male (aOR: 1.8 [95% CI: 1.1-3.1]), disagree that parents will accept HPV vaccine if discussed with other vaccines (aOR: 2.3 [95% CI: 1.3-4.2]), report that 25% to 49% (aOR: 2.8 [95% CI: 1.1-6.8]) or ≥50% (aOR: 7.8 [95% CI: 3.4-17.6]) of parents defer, and express concern about waning immunity (aOR: 3.4 [95% CI: 1.8-6.4]). CONCLUSIONS: Addressing physicians' perceptions about parental acceptance of HPV vaccine, the possible advantages of discussing HPV vaccination with other recommended vaccines, and concerns about waning immunity could lead to increased vaccination rates.
Authors: Alexander G Fiks; Robert W Grundmeier; Stephanie Mayne; Lihai Song; Kristen Feemster; Dean Karavite; Cayce C Hughes; James Massey; Ron Keren; Louis M Bell; Richard Wasserman; A Russell Localio Journal: Pediatrics Date: 2013-05-06 Impact factor: 7.124
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Maura L Gillison; Laia Alemany; Peter J F Snijders; Anil Chaturvedi; Bettie M Steinberg; Steve Schwartz; Xavier Castellsagué Journal: Vaccine Date: 2012-11-20 Impact factor: 3.641
Authors: Sarah Reagan-Steiner; David Yankey; Jenny Jeyarajah; Laurie D Elam-Evans; James A Singleton; C Robinette Curtis; Jessica MacNeil; Lauri E Markowitz; Shannon Stokley Journal: MMWR Morb Mortal Wkly Rep Date: 2015-07-31 Impact factor: 17.586
Authors: Julie S Townsend; C Brooke Steele; Nikki Hayes; Achal Bhatt; Angela R Moore Journal: J Womens Health (Larchmt) Date: 2017-03-06 Impact factor: 2.681
Authors: Emily B Walling; Sherry Dodd; Neil Bobenhouse; Evelyn Cohen Reis; Randy Sterkel; Jane Garbutt Journal: Am J Prev Med Date: 2019-01 Impact factor: 5.043
Authors: Rachel Herman; Louise-Anne McNutt; Mehek Mehta; Daniel A Salmon; Robert A Bednarczyk; Jana Shaw Journal: Hum Vaccin Immunother Date: 2019-03-14 Impact factor: 3.452
Authors: Susan T Vadaparampil; Teri L Malo; Steven K Sutton; Karla N Ali; Jessica A Kahn; Alix Casler; Daniel Salmon; Barbara Walkosz; Richard G Roetzheim; Gregory D Zimet; Anna R Giuliano Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-02 Impact factor: 4.254
Authors: Richard K Zimmerman; Krissy K Moehling; Chyongchiou J Lin; Song Zhang; Jonathan M Raviotta; Evelyn C Reis; Sharon G Humiston; Mary Patricia Nowalk Journal: Vaccine Date: 2016-11-18 Impact factor: 3.641
Authors: Noel T Brewer; Megan E Hall; Teri L Malo; Melissa B Gilkey; Beth Quinn; Christine Lathren Journal: Pediatrics Date: 2016-12-05 Impact factor: 7.124